P53/microRNA-34-induced metabolic regulation: new opportunities in anticancer therapy

• Published in: Molecular cancer Vol. 13; no. 1; p. 115
• Main Authors: Zhang, Ding-Guo, Zheng, Jun-Nian, Pei, Dong-Sheng
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 21-05-2014; BioMed Central
• Subjects: Antineoplastic Agents - therapeutic use; Apoptosis; Apoptosis - drug effects; Cancer; Cell cycle; Cell Cycle Checkpoints - drug effects; Dehydrogenases; Gene expression; Gene Expression Regulation, Neoplastic; Glucose; Humans; Isoenzymes - genetics; Isoenzymes - metabolism; L-Lactate Dehydrogenase - genetics; L-Lactate Dehydrogenase - metabolism; Metabolic disorders; Metabolic Networks and Pathways; Metabolism; MicroRNAs; MicroRNAs - agonists; MicroRNAs - genetics; MicroRNAs - metabolism; Molecular Targeted Therapy; Mutation; Neoplasms - genetics; Neoplasms - metabolism; Neoplasms - pathology; Neoplasms - therapy; Proto-Oncogene Proteins c-myc - genetics; Proto-Oncogene Proteins c-myc - metabolism; Review; Signal Transduction; Sirtuin 1 - genetics; Sirtuin 1 - metabolism; Studies; Transcription factors; Tumor Suppressor Protein p53 - agonists; Tumor Suppressor Protein p53 - genetics; Tumor Suppressor Protein p53 - metabolism
• ISSN: 1476-4598; 1476-4598
• DOI: 10.1186/1476-4598-13-115

MicroRNA-34 (miR-34) is directly regulated by p53, and its potential tumor suppressive roles have been studied extensively. As a p53-induced microRNA, miR-34 functions as a tumor suppressor by playing a role in cell cycle arrest, apoptosis and metabolic regulation. Among these p53/miR-34 associated processes, apoptosis and cell cycle arrest are known as essential for p53/miR-34-mediated tumor suppression. P53-mediated metabolic processes have been shown to play pivotal roles in cancer cell biology. Recent studies have also identified several miR-34 targets involved in p53/miR-34-induced metabolic regulation. However, correlations among these metabolic targets remain to be fully elucidated. In this review, we summarize the current progress in the field of metabolic regulation by the p53/miR-34 axis and propose future directions for the development of metabolic approaches in anticancer therapy.